Photonz has successfully produced about 20 tons of algal omega-3 eicosapentaenoic acid.
Photonz Corp. (Auckland, New Zealand) has announced the successful transfer of its proprietary omega-3 EPA to a contract facility in Canada where it can then be manufactured on an industrial level.
Earlier this year, the company announced that it would soon enter the burgeoning omega-3 market with EPA derived from a proprietary strain of microalgae. The company has since transferred, duplicated, and scaled up its algae culture at a Canadian facility, ultimately producing around 20 tons of its fermented final product.
“As a result of the success of this project I have confirmed to our investors that we remain on track to manufacture, in 2012, an industrial scale end-product that addresses a massive opportunity in the $60 billion cardiovascular disease market,” said Photonz chief executive Greg Moss-Smith.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.